first you, now expecting updates FDA decisions results. XXXX. I'll and with regulatory first half our key and Thank progress new drug in an are clinical regulatory providing filings update commercial of .
Beginning upcoming before on Mihales. discuss X milestones, the our financial we application supplemental on
I for Fanapt on disorder. First, bipolar
December in last and year, episodes discussed, of previously in clinical bipolar Phase acute results announced with disorder As I in adults. we positive in manic our study III mixed of Fanapt
and disorder of opportunity XXXX. of in Our Fanapt disorder date prevalence of this approximately up new potential by estimated been bipolar April as number target now bipolar high a believe in accepted States. the disorder the supplemental set expansion FDA, the drug adults adult We the the has has been significant higher bipolar The to United XXx than action label X, represents franchise, application approximately for is population prevalence prevalence a I in estimated and for schizophrenia. Fanapt X%, the given the U.S. that
supplemental our opportunity, for FDA, insomnia, We has and March XXXX. the target a the for been option set as also HETLIOZ by that meaningful represent insomnia HETLIOZ exciting X, and accepted insomnia for been action provide commercial new has in now patients. date HETLIOZ therapeutic believe could for drug an application On
studies FDA support approximately the this demonstrate believe is of by as substantial for database tradipitant regulatory clinical of decision indication we tradipitant package to The that in this the with application supported efficacy tolerability new we on mid-XXXX. on evidence of patients well as drug results a Additionally, gastroparesis, a of expect our drug. X safety this by
The at longest multiple for with patient the than treated X patients years. treated having expanded more access for least been continues X months program and
On motion in Phase the sickness this second reported, in we May already announced tradipitant with XX% previously the study as in continuing the is study and tradipitant, positive of side, clinical over initiated III of of from have year, of study Phase now the tradipitant first motion treatment a sickness. III We results enrolled.
on therapeutic sickness to program, of upon for which wide plan multiple includes robust progress We clinical approval we tradipitant sickness motion completion development program. products this clinical the the a pursue motion continue range update to areas. tradipitant development of of a And of FDA pipeline, across outside
the Turning and our are the our therapy the during results. team commercial financial into performance tasimelteon, continues these pleased commercial to year. prescribers. X HETLIOZ, the to our and generic months account environment to challenging and of to tirelessly of work with Taking delivered On at-risk solid we progress performance first due on launch support challenges, despite patients
Fanapt, is and on indication in bipolar currently if capitalize approved we approved. positioned Fanapt well the on remain On the driving to ensuring of market schizophrenia growth focused
compared XXXX by XXXX XX% in for the to begin Total the I'll to $XXX.X before summarizing for decrease of $XXX.X XXXX. period discuss the quarter months months were third the turning results, million, first revenues same financial our XXXX. a first million of On X of X
The a increase to during decrease generic was significant HETLIOZ decrease on a volume. XXXX. decrease in attributable net sales deductions, and at-risk in the an for X by for of net offset XX% version performance of price partially sales launch product The had product million impact were X months the million to XXXX period first net months to a saw HETLIOZ the XXXX. in $XX.X of of HETLIOZ $XXX.X a first compared same of
has Our in to for first higher quarter throughout unit HETLIOZ recent periods at net XXXX. inventory pharmacy sales of compared a product stocking sales prior and of reflected increase customers XXXX significant the specialty resulted as
sales $XX.X in months X% reflect Turning same XXXX. for X of million for compared first the period of the to product net Fanapt. million to XXXX $XX.X a decrease Fanapt
XXXX, XXXX. X $X.X compared for net months million For income recorded the a to Vanda of first $X.X the of in period net loss million of same
of for for our by provision $X.X provision first expenses income to driven Fanapt as early-stage the by included program, goods of X $X.X SG&A $XX and million partially million XXXX compared an $XXX.X decreases expenses months was program our driven cost and first of Net decrease months increases period clinical of The the our tax late-stage in same primarily tax million for related activities sold. XXXX R&D in million million $XXX.X the by in Operating period to and for income lower tradipitant to offset lower an of primarily our lower for income development related decrease to ASO expenses were XXXX. the R&D X program. expenses, VQW-XXX XXXX. compared was The same
The and decrease the our sales expenses was decrease X% sold and HETLIOZ lower due to is net in with activities in primarily products. expenses driven by HETLIOZ of the for BMS lower XX% from product SG&A marketing, commercial cost associated royalty on XXXX. goods to product support commercial sales to The net lower December sales rate in effective owed
compared and cash marketable million XX, XXXX, to XX, December and referred of compared increase of XXXX. cash representing equivalents $XXX.X $XX to of as cash an increase cash, an September securities million to was million XX, XXXX, September Vanda's as $XX.X to
at-risk volume. performance to The generic Turning the sales the $XX.X XX% of net third Total HETLIOZ the of third a in for product quarter $XX.X a quarter million impact revenues continued decrease net decrease now sales million a to $XX.X third of product XXXX. compared quarterly of were was million million, significant XXXX. XX% on the have third for to third quarter XXXX. compared The XXXX, to the quarter attributable XXXX HETLIOZ a a of our in decrease of of to results. $XX.X decrease quarter version were HETLIOZ for in during launch
unit compared Our product quarter higher as HETLIOZ to as the sales XXXX net first of periods. recent reflected reported sales for
at of customers continued the elevated inventory end the unit inventory which unit of quarter partially sales, pharmacy of the product XXXX. was XXXX at increase HETLIOZ customers resulted first net during the sales throughout lower quarter at quarter reflect The specialty attributable specialty during a XXXX of sales the reduction levels significant pharmacy higher to first XXXX. in of third stocking of the
net million inventory gross attributable $XX.X wholesaler level the to unfavorable the second during quarter destocking quarters third net at and between the This was Fanapt and in XXXX to period. of adjustments Fanapt the $XX compared the Turning net of XX% million Fanapt. Fanapt third for XXXX an XX% by now XXXX. decreased third the third quarter sales were in in $XX.X of XXXX, product quarter of to sales decrease quarter of product to second compared decrease as million the primarily XXXX. of to
Fanapt third the prescriptions reported of decreased compared to approximately by IQVIA XXXX, as second quarter Xponent X% in the of quarter by XXXX.
of For $X.X the net net quarter to of million the recorded quarter of of million for Vanda income third XXXX, XXXX. third $X.X compared income
income decreased goods our to December in product of royalty an commercial income the the for for Net for due net million the net in products. primarily sales commercial to million compared the for expenses in third driven BMS to $X.X the XXXX of products, of second same $XX.X product and provision our early-stage the XXXX our $X.X million $XX.X $XX.X program to X% owed decrease development sales on compared in to as R&D primarily Operating decrease decrease activities was effective lower tax in on the driven to related benefit HETLIOZ by of cost quarter of million rate quarter to of marketing lower by sales SG&A million an by program, $XX.X of of income third third third as on were Operating spending ASO related expenses the period XX% XXXX. tax compared SG&A quarter in activities late-stage to expenses $X.X Fanapt XXXX. was XXXX. from million expenses and lower and lower spending million The to lower quarter This and sales in quarter sold XXXX. expenses XXXX related HETLIOZ included our
of market the of at is of for a HETLIOZ surrounding the HETLIOZ, ongoing XXXX U.S. for of treatment uncertainties time. patent this as financial version launch to HETLIOZ litigation generic provide Vanda a Given unable guidance Non-XX at-risk and result the the
significantly continue future generic net Vanda at-risk sales a related decline to in product of will potentially the guidance future financial ability launch provide in will to its periods. periods, likely in version HETLIOZ evaluate the HETLIOZ of U.S. to
of to constrained not probable revenue significant months company first the HETLIOZ sales Additionally, reversal. for net product the of X an amount XXXX
experience variability variable could HETLIOZ resolved. product future uncertainties As are net in remaining with periods a associated result, sales as the consideration
back the With that, call to turn Mihales. now I'll
